Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034335071> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2034335071 endingPage "359" @default.
- W2034335071 startingPage "353" @default.
- W2034335071 abstract "Obsessive-compulsive disorder (OCD) often responds inadequately to serotonin reuptake inhibitors (SRIs). A case series reported substantial response to once-weekly oral morphine. We conducted a placebo-controlled, double-blind trial to investigate whether once-weekly oral morphine is effective in SRI-resistant OCD.Subjects with DSM-IV-defined OCD for > or =3 years who had failed > or =2 adequate SRI trials and had a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of > or =20 were recruited. Current medications were continued. Subjects were randomly assigned to random-order, 2-week blocks of once-weekly morphine, lorazepam, and placebo. Week 2 dosage was increased, decreased, or maintained depending on response and side effects.We enrolled 23 subjects, who had failed 2 to 6 SRI trials. The median screening Y-BOCS score was 29. The median Y-BOCS score after morphine (highest dose) was 25 (median decrease = 13%). Seven subjects (30%) were responders (Y-BOCS decreases > or =25%). The median Y-BOCS score after lorazepam (highest dose) was 27 (median decrease = 6%). Four subjects (17%) responded to lorazepam; 1 was a morphine responder. The median Y-BOCS score after placebo (highest dose) was 27 (median decrease = 7%), and no subject responded. Responses differed significantly among the 3 conditions (Friedman 2-way analysis of variance, chir(2) = 13.92, df = 2, p = .01). Wilcoxon matched-pairs signed-rank tests (T = 56.5, p = .05) showed significance for morphine versus placebo but not lorazepam versus placebo.Our results support the hypothesis that once-weekly oral morphine can reduce symptoms in some treatment-resistant OCD patients. The mechanism of action is unknown. Further studies of mu-agonists and glutamate antagonists are warranted." @default.
- W2034335071 created "2016-06-24" @default.
- W2034335071 creator A5026611514 @default.
- W2034335071 creator A5028864050 @default.
- W2034335071 creator A5030348741 @default.
- W2034335071 creator A5032525271 @default.
- W2034335071 creator A5063031637 @default.
- W2034335071 creator A5075024436 @default.
- W2034335071 date "2005-03-15" @default.
- W2034335071 modified "2023-10-10" @default.
- W2034335071 title "Double-Blind Treatment With Oral Morphine in Treatment-Resistant Obsessive-Compulsive Disorder" @default.
- W2034335071 doi "https://doi.org/10.4088/jcp.v66n0312" @default.
- W2034335071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15766302" @default.
- W2034335071 hasPublicationYear "2005" @default.
- W2034335071 type Work @default.
- W2034335071 sameAs 2034335071 @default.
- W2034335071 citedByCount "103" @default.
- W2034335071 countsByYear W20343350712012 @default.
- W2034335071 countsByYear W20343350712013 @default.
- W2034335071 countsByYear W20343350712014 @default.
- W2034335071 countsByYear W20343350712015 @default.
- W2034335071 countsByYear W20343350712016 @default.
- W2034335071 countsByYear W20343350712017 @default.
- W2034335071 countsByYear W20343350712018 @default.
- W2034335071 countsByYear W20343350712019 @default.
- W2034335071 countsByYear W20343350712020 @default.
- W2034335071 countsByYear W20343350712021 @default.
- W2034335071 countsByYear W20343350712022 @default.
- W2034335071 countsByYear W20343350712023 @default.
- W2034335071 crossrefType "journal-article" @default.
- W2034335071 hasAuthorship W2034335071A5026611514 @default.
- W2034335071 hasAuthorship W2034335071A5028864050 @default.
- W2034335071 hasAuthorship W2034335071A5030348741 @default.
- W2034335071 hasAuthorship W2034335071A5032525271 @default.
- W2034335071 hasAuthorship W2034335071A5063031637 @default.
- W2034335071 hasAuthorship W2034335071A5075024436 @default.
- W2034335071 hasConcept C126322002 @default.
- W2034335071 hasConcept C142724271 @default.
- W2034335071 hasConcept C15744967 @default.
- W2034335071 hasConcept C204787440 @default.
- W2034335071 hasConcept C27081682 @default.
- W2034335071 hasConcept C2777389121 @default.
- W2034335071 hasConcept C2779706987 @default.
- W2034335071 hasConcept C42219234 @default.
- W2034335071 hasConcept C71924100 @default.
- W2034335071 hasConcept C99476002 @default.
- W2034335071 hasConceptScore W2034335071C126322002 @default.
- W2034335071 hasConceptScore W2034335071C142724271 @default.
- W2034335071 hasConceptScore W2034335071C15744967 @default.
- W2034335071 hasConceptScore W2034335071C204787440 @default.
- W2034335071 hasConceptScore W2034335071C27081682 @default.
- W2034335071 hasConceptScore W2034335071C2777389121 @default.
- W2034335071 hasConceptScore W2034335071C2779706987 @default.
- W2034335071 hasConceptScore W2034335071C42219234 @default.
- W2034335071 hasConceptScore W2034335071C71924100 @default.
- W2034335071 hasConceptScore W2034335071C99476002 @default.
- W2034335071 hasIssue "03" @default.
- W2034335071 hasLocation W20343350711 @default.
- W2034335071 hasLocation W20343350712 @default.
- W2034335071 hasOpenAccess W2034335071 @default.
- W2034335071 hasPrimaryLocation W20343350711 @default.
- W2034335071 hasRelatedWork W169126297 @default.
- W2034335071 hasRelatedWork W1978968340 @default.
- W2034335071 hasRelatedWork W2100709866 @default.
- W2034335071 hasRelatedWork W2110815511 @default.
- W2034335071 hasRelatedWork W2159719431 @default.
- W2034335071 hasRelatedWork W2406942910 @default.
- W2034335071 hasRelatedWork W2756066498 @default.
- W2034335071 hasRelatedWork W3092530387 @default.
- W2034335071 hasRelatedWork W4237789722 @default.
- W2034335071 hasRelatedWork W2202661267 @default.
- W2034335071 hasVolume "66" @default.
- W2034335071 isParatext "false" @default.
- W2034335071 isRetracted "false" @default.
- W2034335071 magId "2034335071" @default.
- W2034335071 workType "article" @default.